Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06033534
Other study ID # ATinFE
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 1, 2023
Est. completion date July 1, 2025

Study information

Verified date April 2024
Source Università Vita-Salute San Raffaele
Contact Giacomo Placella, MD
Phone 3927123432
Email giacomo.placella@hsr.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, single-center, double-blind randomized clinical trial aimed at evaluating the efficacy and safety of the extended-release antibiotic device, STIMULAN, in preventing infections in patients with open fractures. The study will enroll 40 patients from IRCSS San Raffaele's Emergency Department and Orthopedics and Traumatology Unit. Patients will be stratified into high-risk and low-risk infectious subgroups and randomized into either the intervention group receiving the antibiotic device or the control group receiving no device. The follow-up period will last for 5 days, with data collection at specified intervals. Standard laboratory tests will be utilized to monitor the patient's inflammatory response.


Description:

This study is a prospective, single-center, randomized clinical trial with a double-blind design for both the patient and the evaluator. The aim is to assess the efficacy and safety of the extended-release antibiotic device STIMULAN in preventing infections in patients with open fractures. The trial will be a randomized study that will enroll two cohorts of patients with open fractures, sourced from both the Emergency Department of IRCSS San Raffaele and the Orthopedics and Traumatology Unit. Fractures will be classified according to the Gustilo Classification. Patients requiring surgical repair of the exposed fracture will be randomized to receive either the extended-release antibiotic device or no device at all. The randomization of this study is stratified, with a 1:1 ratio, and 40 patients will be divided into two groups: Intervention group: extended-release antibiotic device Control group: no device Two stratification subgroups will be included: High-risk infectious subgroup Low-risk infectious subgroup For the definition of stratification, please refer to Section 9.1, Risk Assessment Table for Stratification. Patients will be followed for a duration of 5 days, and follow-up data will be collected at established intervals. According to recent studies, the onset of initial infections occurs between 24 and 72 hours following the episode of open fracture. Therefore, a 5-day period is deemed a reasonable time frame for constant monitoring. Standard-of-care laboratory tests such as white blood cell count, C-reactive protein, erythrocyte sedimentation rate, and procalcitonin will also be collected and analyzed to determine the patient's inflammatory response.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date July 1, 2025
Est. primary completion date July 1, 2024
Accepts healthy volunteers No
Gender All
Age group N/A to 65 Years
Eligibility Inclusion Criteria: - Open fractures of any type and location - Fractures classified as Gustilo-Anderson Type I, II, IIIa, IIIb, IIIc - Patients requiring surgical intervention for fracture correction - Patients with no contraindications for antibiotic treatment - Patients providing informed consent Exclusion Criteria: - Patients with active infections - Patients with a history of allergies or adverse reactions to the antibiotics used in the extended-release device - Patients with severe renal or hepatic insufficiency - Non-cooperative patients or those who are unable to adhere to follow-up visits or study procedures due to physical or mental limitations or severe neurological illness - Patients who have undergone spinal surgery

Study Design


Related Conditions & MeSH terms


Intervention

Device:
STIMULAN
Procedures: Surgical repair of the open fracture, as per standard-of-care guidelines. Insertion of the STIMULAN device at the site of the fracture. Standard post-operative care, including monitoring of inflammatory markers and clinical signs of infection.

Locations

Country Name City State
Italy Ospedale San Raffaele Milan

Sponsors (1)

Lead Sponsor Collaborator
Università Vita-Salute San Raffaele

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Infected Open Fracture The primary outcome measure of this clinical trial is the incidence of bacterial infections following surgical intervention for open fractures in both the intervention and control arms. This will be quantified as the number of confirmed bacterial infections per total number of participants in each arm, expressed as a percentage. 5 days
See also
  Status Clinical Trial Phase
Completed NCT01496014 - Assessment of Severe Extremity Wound Bioburden at the Time of Definitive Wound Closure or Coverage
Recruiting NCT03765567 - Placement of Antibiotic Powder in Wounds During the Emergency Room Phase 4
Not yet recruiting NCT02948387 - Preventing Infections in Orthopaedic Patients N/A
Completed NCT04418882 - Septic Management and Outcome of Open Fracture
Recruiting NCT05785182 - OCT in Open Fracture and Infected Fracture
Completed NCT00299052 - Efficacy of DBM on Fractures of the Shinbone (Tibia) Phase 4
Terminated NCT03560232 - Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens Phase 4